[go: up one dir, main page]

ES2179110T3 - Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral. - Google Patents

Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral.

Info

Publication number
ES2179110T3
ES2179110T3 ES95929954T ES95929954T ES2179110T3 ES 2179110 T3 ES2179110 T3 ES 2179110T3 ES 95929954 T ES95929954 T ES 95929954T ES 95929954 T ES95929954 T ES 95929954T ES 2179110 T3 ES2179110 T3 ES 2179110T3
Authority
ES
Spain
Prior art keywords
purin
methanol
amino
succinate
cyclopropylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95929954T
Other languages
English (en)
Inventor
Susan Mary Daluge
Jeffrey Douglas Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2179110T3 publication Critical patent/ES2179110T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA SAL DE SUCCINATO DE (()1S,4R())-CIS-[[]2-AMINO-6-(()CICLOPROPILAMINO())-9H-PURIN-9ILO[]]-2-CICLOPENTENO-1-METANOL O A UN SOLVATO DE LA MISMA, A FORMULACIONES FARMACEUTICAS QUE CONTIENEN DICHO COMPUESTO O FORMULACIONES FARMACEUTICAS, Y A SU USO EN TERAPIA MEDICA O EN METODOS DE TRATAMIENTO O PROFILAXIS DE UNA INFECCION VIRICA, ESPECIFICAMENTE INFECCION POR VIRUS DE INMUNODEFICIENCIA HUMANA (VIH) Y VIRUS DE HEPATITIS B (VHB).
ES95929954T 1994-08-26 1995-08-25 Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral. Expired - Lifetime ES2179110T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417249A GB9417249D0 (en) 1994-08-26 1994-08-26 A novel salt

Publications (1)

Publication Number Publication Date
ES2179110T3 true ES2179110T3 (es) 2003-01-16

Family

ID=10760434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95929954T Expired - Lifetime ES2179110T3 (es) 1994-08-26 1995-08-25 Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral.

Country Status (23)

Country Link
EP (1) EP0777669B1 (es)
JP (1) JPH10505593A (es)
KR (1) KR100376240B1 (es)
CN (1) CN1051550C (es)
AT (1) ATE220067T1 (es)
AU (1) AU702618B2 (es)
BR (1) BR9508629A (es)
CA (1) CA2198010C (es)
DE (1) DE69527294T2 (es)
DK (1) DK0777669T3 (es)
ES (1) ES2179110T3 (es)
FI (1) FI120403B (es)
GB (1) GB9417249D0 (es)
HU (1) HU221302B1 (es)
IL (1) IL115074A (es)
MX (1) MX9701273A (es)
NO (1) NO315200B1 (es)
NZ (1) NZ291862A (es)
PT (1) PT777669E (es)
RU (1) RU2145324C1 (es)
SI (1) SI0777669T1 (es)
WO (1) WO1996006844A1 (es)
ZA (1) ZA957166B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
CA2289654A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
AU7912398A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
CZ299083B6 (cs) * 1997-11-27 2008-04-16 Lonza Ag Zpusob výroby aminoalkoholu
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9903091D0 (en) 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
BR0109602A (pt) * 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
HUP0302068A3 (en) * 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
RU2242243C2 (ru) * 2001-09-27 2004-12-20 Вертелецкий Павел Васильевич Композиции и способы потенцирования терапевтических эффектов интерферонов
KR20060101476A (ko) * 2003-10-27 2006-09-25 머크 앤드 캄파니 인코포레이티드 Ｃｃｒ-2 길항제 염
EP1905772A1 (en) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2305680A3 (en) * 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
ES2729824T3 (es) 2011-04-08 2019-11-06 Laurus Labs Ltd Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3025492A1 (de) * 1980-07-04 1982-02-04 Siemens AG, 1000 Berlin und 8000 München Filterelement fuer die optische nachrichtentechnik
ZA83626B (en) * 1982-02-01 1983-12-28 Syntex Inc Substituted 9-(1 or 3-monoacyloxy or 1, 3-diacyloxy-2-propoxy-methyl purines as antiviral agent
US5003462A (en) * 1988-05-31 1991-03-26 International Business Machines Corporation Apparatus and method for implementing precise interrupts on a pipelined processor with multiple functional units with separate address translation interrupt means
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate

Also Published As

Publication number Publication date
ATE220067T1 (de) 2002-07-15
CA2198010A1 (en) 1996-03-07
HU221302B1 (en) 2002-09-28
BR9508629A (pt) 1997-11-25
SI0777669T1 (en) 2002-12-31
KR970705563A (ko) 1997-10-09
NO970847D0 (no) 1997-02-25
DE69527294D1 (en) 2002-08-08
NZ291862A (en) 1998-02-26
DK0777669T3 (da) 2002-10-28
CA2198010C (en) 2006-05-02
FI120403B (fi) 2009-10-15
JPH10505593A (ja) 1998-06-02
AU3350995A (en) 1996-03-22
CN1051550C (zh) 2000-04-19
FI970786A0 (fi) 1997-02-25
DE69527294T2 (de) 2003-02-13
PT777669E (pt) 2002-11-29
NO315200B1 (no) 2003-07-28
NO970847L (no) 1997-02-25
CN1156456A (zh) 1997-08-06
GB9417249D0 (en) 1994-10-19
WO1996006844A1 (en) 1996-03-07
ZA957166B (en) 1997-02-25
IL115074A (en) 1998-10-30
FI970786L (fi) 1997-02-25
MX9701273A (es) 1997-05-31
KR100376240B1 (ko) 2003-06-11
HUT77222A (hu) 1998-03-02
EP0777669B1 (en) 2002-07-03
EP0777669A1 (en) 1997-06-11
AU702618B2 (en) 1999-02-25
RU2145324C1 (ru) 2000-02-10
IL115074A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
ES2179110T3 (es) Succinato 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral.
CA2253736A1 (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
EA199900773A1 (ru) Противомикробная профилактика и лечение заболеваний, вызванных вирусом иммунодефицита человека и другими инфекциями
ES2069582T3 (es) Nucleosidos terapeuticos.
MY104575A (en) Therapeutic nucleosides.
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
AP2000001971A0 (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine.
CO4520283A1 (es) Agentes antivirales
BR9916893A (pt) Tratamento
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
GR3014952T3 (en) Use of an immunoglobulin-containing composition in the prophylaxis and therapy of AIDS of human.
KR950700315A (ko) 이중 작용을 하는 2',5'-올리고아데닐레이트 항비루스성 유도체와 그의 용도
ATE183508T1 (de) Therapeutische nukleoside
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
ES2195861T3 (es) Uso de (ir,4s)-4-(6-amino-9h-purin-9-il)-2-ciclopenten-1-metanol en vhb.
AU6751794A (en) Extracts of piliostigma thonningii, the use thereof and formulations containing them
BR0013741A (pt) Composto, processo para a preparação de um composto, medicamento, agente terapêutico ou profilático para doenças infecciosas fúngicas, cepa, uso de um composto, método para o tratamento ou a prevenção de uma infecção fúngica, e, composição farmacêutica
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
RU93048568A (ru) 14,14,14-трифтор-12-оксатетрадекановая кислота, липидный ингибитор вируса иммунодефицита человека